News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
397,071 Results
Type
Article (17359)
Company Profile (124)
Press Release (379588)
Section
Business (135527)
Career Advice (861)
Deals (24615)
Drug Delivery (61)
Drug Development (47577)
Employer Resources (70)
FDA (8623)
Job Trends (8608)
News (220339)
Policy (18679)
Tag
Academia (687)
Africa (436)
Alliances (31196)
Alzheimer's disease (482)
Approvals (8594)
Arizona (67)
Artificial intelligence (45)
Asia (25824)
Australia (3401)
Bankruptcy (203)
Best Places to Work (5959)
Biosimilars (42)
Biotechnology (61)
C2C Services and Suppliers (32362)
California (996)
Canada (589)
Cancer (235)
Career advice (737)
Cell therapy (49)
China (77)
Clinical research (38712)
Collaboration (68)
Colorado (35)
Compensation (47)
Connecticut (46)
COVID-19 (948)
Data (167)
Diabetes (32)
Diagnostics (2730)
Drug pricing (51)
Earnings (56160)
Employer resources (64)
Europe (52232)
Events (61159)
Executive appointments (118)
FDA (8722)
Florida (126)
Funding (71)
Gene therapy (47)
GLP-1 (317)
Government (1579)
Healthcare (7382)
Hotbed/Location (280073)
Illinois (114)
Indiana (82)
Infectious disease (954)
Inflammatory bowel disease (52)
Interviews (107)
IPO (10860)
Job creations (2735)
Job search strategy (679)
Kansas (61)
Layoffs (249)
Legal (5024)
Lung cancer (50)
Manufacturing (54)
Maryland (140)
Massachusetts (902)
Medical device (4611)
Medtech (4614)
Mergers & acquisitions (13688)
Metabolic disorders (127)
Michigan (57)
Minnesota (101)
Neuroscience (549)
New Jersey (374)
New York (324)
NextGen Class of 2024 (2850)
Non-profit (1175)
North Carolina (364)
Northern California (458)
Obesity (79)
Ohio (48)
Opinion (135)
Patents (44)
Pennsylvania (270)
People (39943)
Pharmaceutical (60)
Phase I (10714)
Phase II (16616)
Phase III (14120)
Pipeline (94)
Podcasts (38)
Policy (42)
Postmarket research (1725)
Preclinical (4307)
Press Release (72)
Rare diseases (70)
Real estate (3769)
Regulatory (12538)
Research institute (780)
Resumes & cover letters (126)
South America (664)
Southern California (409)
Startups (2206)
Texas (125)
United States (4503)
Vaccines (112)
Washington State (90)
Weight loss (67)
Date
Today (55)
Last 7 days (340)
Last 30 days (1244)
Last 365 days (20891)
2024 (14694)
2023 (22807)
2022 (31095)
2021 (32579)
2020 (30640)
2019 (23684)
2018 (18364)
2017 (19763)
2016 (18575)
2015 (22497)
2014 (18492)
2013 (15579)
2012 (16767)
2011 (17458)
2010 (16480)
397,071 Results for "novartis pharmaceutical corporation".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Approvals
Novartis Pushes Kisqali Into Earlier Stages of Breast Cancer, Nearly Doubles Eligible Patient Population
The FDA’s approval of Kisqali in combination with an aromatase inhibitor allows Novartis to target patients with earlier breast cancer who are at risk of recurrence.
September 18, 2024
·
2 min read
·
Tristan Manalac
Cardiovascular disease
Novartis Plots Leqvio Expansion After Lowering Cholesterol in Phase III Study
Armed with new late-stage data on reducing low-density lipoprotein cholesterol, Novartis is positioning its siRNA therapy Leqvio as a preventive treatment for atherosclerotic cardiovascular disease.
August 29, 2024
·
2 min read
·
Tristan Manalac
Business
Novartis, Versant Launch RNA Kidney Medicines—Focused Borealis
Looking to build on the success of Chinook Therapeutics, founded by Versant in 2019 and acquired by Novartis last year, the companies on Thursday launched Borealis Biosciences with $150 million in funding to develop RNA therapeutics for kidney diseases.
August 22, 2024
·
2 min read
·
Kate Goodwin
Legal
Novartis Loses Court Case to Block Entresto Generics After FDA Denies Petition
On the heels of the FDA’s denial of its petition, a Delaware district court on Monday handed Novartis another loss in its efforts to keep the market free of Entresto copycats.
August 13, 2024
·
2 min read
·
Tristan Manalac
Deals
MorphoSys and Novartis Sign Delisting Agreement and Intend to Implement a Merger Squeeze-out of MorphoSys’ Minority Shareholders
MorphoSys AG announced that the company has entered into a delisting agreement with Novartis BidCo AG and Novartis AG following the successful closing of the acquisition of MorphoSys by Novartis in May 2024.
June 20, 2024
·
10 min read
Business
Novartis Canada and Clarius Mobile Health Challenge Standard of Care for Psoriatic Arthritis With New Partnership
Novartis Pharmaceuticals Canada Inc. is pleased to announce a partnership with Clarius Mobile Health as part of a dedicated effort to aid in early detection of psoriatic arthritis in Canada.
May 27, 2024
·
4 min read
Earnings
Despite Layoff Announcements, Novartis Beats Q2 Expectations
Novartis’ second-quarter earnings, announced Thursday, show strong performance of its blockbuster drugs, prompting the company to raise its year-end guidance.
July 18, 2024
·
2 min read
·
Tyler Patchen
Collaboration
Novartis, Dren Bio Ink Potential $3B Deal for Anti-Myeloid Bispecific Antibodies for Cancer
Novartis continues its dealmaking spree with a bet on Dren Bio’s Targeted Myeloid Engager and Phagocytosis platform to develop bispecific antibodies in oncology.
July 25, 2024
·
2 min read
·
Tristan Manalac
Novartis Canada’s statement on CADTH draft recommendations for LEQVIO (inclisiran)
Novartis Pharmaceuticals Canada Inc. (Novartis Canada) is deeply disappointed with the draft recommendations of the Canadian Drug Expert Committee (CDEC) issued by the Canadian Agency for Drugs and Technologies in Health (CADTH) for LEQVIO® (inclisiran).
March 21, 2024
·
4 min read
Deals
Ad hoc: Novartis BidCo Germany AG Intends to Implement a Merger Squeeze-out of MorphoSys AG’s Minority Shareholders
MorphoSys AG announces that Novartis BidCo Germany AG informed the MorphoSys AG Management Board of its intention to merge MorphoSys AG as transferring company into Novartis BidCo Germany AG.
June 20, 2024
·
4 min read
1 of 39,708
Next
